Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
January 28, 2014
Homogeneous RegMed is turning
January 27, 2014
The RegMed piñata
January 27, 2014
It’s all about suspicions and carryover
January 24, 2014
Slam, bam and no thank you
January 24, 2014
RegMed crumbles - lacking short-tern conviction
January 23, 2014
Retesting the regenerative zone
January 23, 2014
Optimism gets muddled
January 22, 2014
Waiting for who and what blinks?
January 22, 2014
Stretching pricing vulnerability
January 21, 2014
Gauging the trade
35 companies, 1 interpreter!
Insight, foresight and recommendation
SOLD to Intrexon (NYSE: XON). MEDS stockholders will receive $0.27 in cash and $1.08 worth of XON’s common stock, based on the 20-day volume-weighted average price of the stock immediately prior to closing. MEDS platform has been saved; having NOT being able to raise capital – having been on a “thin” string for a while - it was the only “play or option” left!
goneMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors